CLBK

Columbia Financial, Inc. 2024 Q3 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2024. Columbia Financial, Inc. is a Delaware corporation and the parent holding company of Columbia Bank, MHC. The company operates as an accelerated filer. As of November 4, 2024, there were 104,723,454 shares of common stock issued and outstanding. The company recently completed the merger of Freehold Bank into Columbia Bank effective October 5, 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Decline: Net income decreased 32.3% quarter-over-quarter and 67.6% year-over-year (YTD). The decline is primarily driven by a compression in net interest income due to rising funding costs and a significant increase in the provision for credit losses.
• Net Interest Margin Compression: The net interest margin decreased 22 basis points to 1.84% for the quarter and 47 basis points to 1.80% YTD. While yields on earning assets increased (loans up 53 bps to 5.00%), the cost of interest-bearing liabilities rose more sharply (up 82 bps to 3.52% for the quarter).
• Asset Quality Deterioration: Non-performing loans increased to $28.0 million (0.36% of gross loans) from $12.6 million at year-end 2023. This increase was largely driven by a single healthcare facility borrower ($9.2 million exposure) placed on non-accrual. Net charge-offs for the nine months ended September 30, 2024, totaled $8.2 million, compared to $2.3 million in the prior year period.
• Balance Sheet Shifts: Total assets increased slightly by $40.9 million. Cash and cash equivalents decreased by $139.7 million, primarily used to purchase debt securities ($266.9 million) and fund stock repurchases. Deposits grew by $111.5 million, driven by certificates of deposit, while borrowings decreased by $108.1 million.

Guidance, Outlook, and Risks

• Capital Management: The company has paused its stock repurchase program to retain capital. As of September 30, 2024, 741,725 shares remained available under the active repurchase program.
• Liquidity: The company maintains strong liquidity with immediate access to approximately $2.6 billion in funding and over $1.8 billion in unpledged loan collateral. There were no borrowings from the Federal Reserve Discount Window.
• Capital Adequacy: Both the holding company and subsidiary banks exceeded all regulatory capital requirements, maintaining "well-capitalized" status. The Common Equity Tier 1 capital ratio for the company was 13.50%.
• Risk Factors: Key risks include the impact of rising interest rates on net interest margin, credit risk associated with commercial real estate and commercial business loans, and the potential for further deterioration in asset quality if economic conditions worsen. The company noted that the allowance for credit losses is a critical accounting estimate subject to significant judgment.
• Subsequent Events: No material events occurred between September 30, 2024, and the filing date (November 8, 2024).

Investor Verification Checklist

• Asset Quality Concentration: Verify the status and collateral coverage of the single healthcare facility borrower responsible for approximately 60% of the increase in non-performing loans.
• Deposit Cost Sustainability: Assess the sustainability of the 3.52% cost of interest-bearing liabilities and the impact of competitive deposit pricing on future margins.
• Provision Adequacy: Review the qualitative factors driving the $11.6 million YTD provision for credit losses and the specific charge-offs in the commercial business segment ($7.7 million).
• Securities Portfolio: Monitor the unrealized losses on debt securities available for sale ($127.6 million gross unrealized losses) and the impact of potential sales on earnings.
• Capital Retention Strategy: Confirm the duration of the stock repurchase pause and the company's capital deployment strategy given the strong capital ratios.